Research Article

You have free access to this content

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

  1. Philip Raskin1,*,
  2. Titus Gylvin2,
  3. Wayne Weng3,
  4. Louis Chaykin4

Article first published online: 29 JUN 2009

DOI: 10.1002/dmrr.989

Issue

Diabetes/Metabolism Research and Reviews

Diabetes/Metabolism Research and Reviews

Volume 25, Issue 6, pages 542–548, September 2009

Additional Information

How to Cite

Raskin, P., Gylvin, T., Weng, W. and Chaykin, L. (2009), Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab. Res. Rev., 25: 542–548. doi: 10.1002/dmrr.989

Author Information

  1. 1

    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA

  2. 2

    Medical Affairs, Novo Nordisk Inc., Princeton, New Jersey, USA

  3. 3

    Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Inc., Princeton, New Jersey, USA

  4. 4

    Medical Research Unlimited, Aventura, Florida, USA

*Professor of Medicine Clifton and Betsy Robinson Chair in Biomedical Research, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8858 USA.

Publication History

  1. Issue published online: 27 AUG 2009
  2. Article first published online: 29 JUN 2009
  3. Manuscript Accepted: 13 MAY 2009
  4. Manuscript Revised: 2 APR 2009
  5. Manuscript Received: 11 JUL 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (121K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jack L. Leahy, Insulin Therapy in Type 2 Diabetes Mellitus, Endocrinology & Metabolism Clinics of North America, 2012, 41, 1, 119

    CrossRef

  2. 2
    Davida F. Kruger, Intensifying insulin treatment: Options, practical issues, and the role of the nurse practitioner, Journal of the American Academy of Nurse Practitioners, 2012, 24,
    Direct Link:
  3. 3
    Russell D. White, Patient empowerment and optimal glycemic control, Current Medical Research and Opinion, 2012, 1

    CrossRef

  4. 4
    Stefano Del Prato, Antonio Nicolucci, Augusto C. Lovagnini-Scher, Salvatore Turco, Sergio Leotta, Giacomo Vespasiani, Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine—the ELEONOR Study, Diabetes Technology & Therapeutics, 2012, 14, 2, 175

    CrossRef

  5. 5
    Lin Xie, Wenhui Wei, Chunshen Pan, Juan Du, Onur Baser, A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens, Advances in Therapy, 2011, 28, 11, 1000

    CrossRef

  6. 6
    Maka S. Hedrington, Lindsay Pulliam, Stephen N. Davis, Basal Insulin Treatment in Type 2 Diabetes, Diabetes Technology & Therapeutics, 2011, 13, S1, S-33

    CrossRef

  7. 7
    Allen B King, Clinical appraisal of deficiencies of the basal analog insulin, Expert Review of Endocrinology & Metabolism, 2011, 6, 4, 579

    CrossRef

  8. 8
    Dong-Churl Suh, Mark Aagren, Cost–effectiveness of insulin detemir: a systematic review, Expert Review of Pharmacoeconomics & Outcomes Research, 2011, 11, 6, 641

    CrossRef

  9. 9
    Katherine Esposito, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Dario Giugliano, Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials, Metabolic Syndrome and Related Disorders, 2011, 9, 3, 167

    CrossRef

  10. 10
    David R. Owens, Insulin Preparations with Prolonged Effect, Diabetes Technology & Therapeutics, 2011, 13, S1, S-5

    CrossRef

  11. 11
    Scott E. Nelson, Management of patients with type 2 diabetes, Current Medical Research and Opinion, 2011, 27, 10, 1931

    CrossRef

  12. 12
    Anne-Laure Guillermin, Yevgeniy Samyshkin, Donna Wright, Tini Nguyen, Julie Villeneuve, Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis, Journal of Medical Economics, 2011, 14, 2, 207

    CrossRef

  13. 13
    Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review, Journal of Diabetes and its Complications, 2011, 25, 4, 275

    CrossRef

  14. 14
    D. Giugliano, M. Maiorino, G. Bellastella, P. Chiodini, K. Esposito, Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials, International Journal of Clinical Practice, 2011, 65, 5
    Direct Link:
  15. 15
    Dario Giugliano, Maria Ida Maiorino, Giusppe Bellastella, Paolo Chiodini, Katherine Esposito, Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review, Diabetes Research and Clinical Practice, 2011, 92, 1, 1

    CrossRef

  16. 16
    J. Gordon, R. D. Pockett, A. P. Tetlow, P. McEwan, P. D. Home, A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study, International Journal of Clinical Practice, 2010, 64, 12
    Direct Link:
  17. 17
    Edith M. Heintjes, Trine L. Thomsen, Fernie J. A. Penning-van Beest, Torsten E. Christensen, Ron M. C. Herings, Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes, Advances in Therapy, 2010, 27, 4, 211

    CrossRef

  18. 18
    Sanne G Swinnen, Airin CR Simon, Frits Holleman, Joost B Hoekstra, J Hans DeVries, Insulin detemir versus insulin glargine for type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
View Full Article (HTML) Get PDF (121K)